Introduction
A global pandemic known as the SARS-CoV-2 virus has brought on COVID-19. This has significantly impacted people's lives, economy, and healthcare. Frequent symptoms consist of fatigue, coughing, and fever. Some become quite ill, suffering from acute dyspnea (shortness of breath) and other consequences that impact several organs, including the heart, brain, and lungs. COVID-19 can also impact blood cells, resulting in alterations to hemoglobin levels, platelets, white blood cells, and blood coagulation. This article covers various blood-related problems, describes their causes, and offers management advice. It also covers the impact of COVID-19 on individuals who already have blood disorders, as well as the adverse effects of COVID-19 treatments on the blood.
What Are the Hematological Abnormalities in Other Coronaviruses?
Low amounts of platelets and lymphocytes, a kind of white blood cell, can result from infections with SARS-CoV-1 and MERS-CoV. They are referred to as thrombocytopenia and lymphopenia, respectively. These problems, however, are uncommon in infections brought on by other coronaviruses, such as OC43 and 229E, which often only induce symptoms similar to the common cold. Additionally, studies have shown that infections with SARS-CoV-1 and MERS-CoV can result in issues with blood coagulation, including elevated D-dimer levels and prolonged prothrombin times.
These clotting issues may occasionally result in deep vein thrombosis or clots in the veins, or they may impact more than one organ, such as the lungs and bronchi. Even symptoms of disseminated intravascular coagulation (DIC), a dangerous illness in which blood clotting occurs all over the body, have been observed in fatal cases of MERS-CoV. Notably, these coagulation problems appear to be unique to coronaviruses that produce severe respiratory symptoms rather than to other coronaviruses.
What Are Key Findings on COVID-19 Thrombocytopenia and Pseudothrombocytopenia?
Five to 21 percent of COVID-19 patients have been reported to have thrombocytopenia or low platelet counts. According to studies, people with low platelet counts are more likely to die from COVID-19, and more severe instances are associated with a higher risk of thrombocytopenia. Patients with lower platelet counts at admission have a higher risk of death; therefore, tracking platelet counts during hospital stays may help predict outcomes. In contrast to certain illnesses like dengue, when platelet counts may plummet, COVID-19 thrombocytopenia is typically mild.
Studies have indicated that in COVID-19 patients, an increased platelet-to-lymphocyte ratio may indicate a poorer prognosis. Additionally, cases of individuals contracting SARS-CoV-2 infection and going on to develop blood diseases such as thrombotic thrombocytopenic purpura or TTP (tiny blood clots and low platelets causing purple spots) and idiopathic thrombocytopenia purpura or ITP (low platelets causing purple spots) have been made. It has been discovered that Dexamethasone and intravenous immunoglobulin are useful treatments for certain illnesses. Notably, pseudo thrombocytopenia, or the appearance of thrombocytopenia in COVID-19 patients, may occasionally be a false negative result caused by platelet aggregation in specific blood samples. This phenomenon may require confirmation using several testing techniques to prevent false diagnoses.
What Are the Blood Clotting Issues Seen in COVID-19 Patients?
Numerous studies reveal problems with blood coagulation in COVID-19 individuals. This is not like the common clotting diseases. Compared to other patients, COVID-19 patients frequently have higher D-dimer levels and longer prothrombin times. Even greater amounts are seen in severe cases, which may assist in direct treatment and anticipate results. High D-dimer levels at admission can predict that someone who may not survive in the hospital. Around 25 percent of COVID-19 patients in the ICU (intensive care unit) are particularly vulnerable to blood clots. Serious issues, including lung clots, vein clots, or strokes, might result from these clots.
According to some research, half of these clots were discovered within a day after hospital admission. Compared to non-ICU patients, ICU patients have a significantly increased risk of clotting. Better treatments are needed because some individuals still form potentially fatal blood clots when on blood thinners. COVID-19 ICU patients frequently have additional risk factors, such as advanced age or obesity, which might exacerbate clotting. Physicians treating COVID-19 patients in emergencies or during surgery should exercise caution for clot-related problems. Further studies are required to comprehend the coagulation alterations in COVID-19.
What Is the Impact of COVID-19 on Red Blood Cells and Hemoglobin?
Blood that delivers oxygen throughout the body contains less hemoglobin in some sick COVID-19 patients. Four trials were reviewed, and the results indicated that hemoglobin levels were lower in severe COVID-19 patients than in milder cases. Nevertheless, a few investigations failed to detect appreciable variations in hemoglobin levels among COVID-19 patients. Further research is required in this area, even though some researchers recommend measuring hemoglobin levels to gauge a patient's likelihood of becoming ill.
Research has not discovered any significant alterations in the quantity of red blood cells in COVID-19 individuals, but it has identified several structural alterations. The structural components of COVID-19 patients' red blood cells were more damaged, with variations in how their fats were digested.
What Is the Impact of COVID-19 on White Blood Cells?
While three percent to 24 percent of COVID-19 patients have high white blood cell counts (leukocytosis), between 20 and 40 percent of patients have low white blood cell counts (leucopenia). Low lymphocyte counts, or lymphopenia, are also common in COVID-19 patients (30 percent to 75 percent) and are linked to serious diseases.
In extreme situations, there is a decrease in the number of specific white blood cells known as CD4+ and CD8+ T lymphocytes, and these cells exhibit signs of fatigue. Severe instances may have elevated neutrophil counts, and poorer results are associated with a high neutrophil-to-lymphocyte ratio.
In COVID-19 individuals, alterations in the form and properties of platelets and white blood cells (neutrophils) have been noted. The blood contains some immature white blood cells, which may result from the body's reaction to the virus. A cytokine storm, a strong immunological reaction, could be the source of these alterations. These changes can occasionally be reversed by treatment, but further study is required to comprehend their importance fully.
What Is the Impact of COVID-19 on Spleen and Bone Marrow?
Some patients with severe COVID-19 instances have indications of bone marrow involvement. This includes specific cells, such as megakaryocytes, which are involved in the production of platelets, becoming more active. These bone marrow cells showed unusual virus particles under an electron microscope.
Evidence shows that the virus can also impact the spleen, an organ part of the immune system. The spleen contains ACE-2, a receptor that the virus exploits. The virus was discovered in specific splenic regions during the autopsy of COVID-19 patients; it primarily affected the red pulp, where blood cells are filtered. The body's capacity to combat the illness may be hampered by the viral presence's potential to kill immune cells. Research has also revealed alterations in the splenic architecture and reductions in certain immune cells in COVID-19 patients.
What Is the Mechanism Involved Behind Blood Abnormalities in COVID-19?
Blood cells might not function normally in COVID-19 for several reasons.
-
Platelets: These cells aid in blood clotting. As COVID-19 may directly impair platelet formation or cause the body's immune system to destroy them, platelet counts may decline. Blood clots can occur when platelet counts are excessive. This may result from inflammatory blood vessel damage or the body's reaction to the infection.
-
The Fibrinolytic System and Coagulation: In COVID-19, the body's clotting and clot-breakdown mechanisms may not function as intended. This might occur due to the virus causing inflammation, which throws off clotting factor balances. Blood clots may result from an increase in specific clotting-related proteins. Moreover, increased clotting may result from the virus harming pericytes, which are microscopic blood vessel cells.
-
Hemoglobin and Red Blood Cells: COVID-19 may impact hemoglobin, the protein in red blood cells that carries oxygen. Breathing issues could arise due to the blood's ability to carry oxygen being lessened.
-
White Blood Cells: These cells are anti-infective. In COVID-19, the virus may harm the bone marrow, which produces white blood cells, or assault the cells directly. Additionally, low concentrations of specific types of white blood cells may result from the body's immune reaction to the virus. There may occasionally be excess white blood cells, particularly neutrophils, due to viral inflammation or subsequent bacterial infections.
-
Bone Marrow: This is the production site for blood cells. It is possible that COVID-19 directly affects the bone marrow, interfering with blood cell synthesis. This might result from the virus causing an overabundance of immune responses or infecting bone marrow stem cells. These changes may partially explain the anomalies observed in blood cell numbers and function during COVID-19.
What Is the Impact of COVID-19 on Patients With Hematologic Disorders?
-
Red Blood Cell Disorders: Patients with thalassemia (an inherited blood disorder causing the body to make few healthy red blood cells and less hemoglobin) and sickle cell disease or SCD (a genetic condition where red blood cells become crescent-shaped, leading to blockages in blood vessels and reduced oxygen flow) are generally more susceptible to infections, particularly those of the respiratory tract. A common drug for sickle cell disease (SCD) called Hydroxycarbamide has immunosuppressive properties and should be taken with caution. A short research on patients with thalassemia did not reveal that COVID-19 was more severe. Further research is necessary, although certain results indicate that patients with heterozygous beta-thalassemia might be protected against COVID-19.
-
Bleeding and Coagulation Disorders: Large cohort studies on people with coagulation and bleeding disorders who are infected with COVID-19 are not widely available. The COVID-19 clinical signs of a patient with hemophilia (bleeding disorder) resembled those of other patients, with no bleeding incidents. It is unclear whether individuals with idiopathic TTP or ITP might experience a more severe case of COVID-19 infection.
-
Hematologic Cancers: Individuals who have hematologic malignancies are considerably more vulnerable to COVID-19 and other serious infections. Their risk of infection is greatly increased by chemotherapy. Research has indicated that patients with hematologic malignancy who also have COVID-19 infection have a higher death rate than those who only have hematologic malignancy. Variables like age, immunological characteristics, and illness state influence results. The death rate is higher in patients with COVID-19 and hematologic malignancies when they are older, have more comorbidities, have a different type of hematologic malignancy, and are receiving antineoplastic therapy.
The prognosis of patients with hematologic malignancies is affected by various factors. Such patients may be more susceptible to infections due to direct immunosuppressive effects and adverse effects from therapy. Research has not revealed any variations in the initial features of hematologic malignancy patients with or without COVID-19; however, the mortality rate was greater in the COVID-19-positive group.
Infection control is essential to the treatment of hematologic cancer patients. Due to the pandemic, clinicians have had to reconsider and redesign how they provide care for these individuals. Using telemedicine, cutting back on pointless hospital stays, and modifying treatment regimens are some strategies to reduce the chance of contracting the virus.
How Are Hematological Abnormalities in COVID-19 Managed?
-
Platelets: Treatment for severe thrombocytopenia, or low platelet count, is typically unnecessary in COVID-19 patients because it is uncommon. In a few instances, patients made a full recovery even though they developed immune-related disorders that affected their platelets, such as TTP or ITP.
-
Coagulation and Fibrinolytic System: For hospitalized COVID-19 patients, physicians usually advise low-molecular-weight Heparin as a preventative measure against blood clots. Heparin helps COVID-19 patients feel less inflammatory while also preventing blood clots. However, in severe cases when the liver is malfunctioning, bleeding may become more likely; therefore, physicians modify the type and dosage of blood thinners according to the patient's condition. Some patients may still be at risk for blood clots after leaving the hospital, but it is unclear if they will require blood thinners when they get back home. To ascertain whether blood thinners must be used continuously after hospital discharge, more research is required.
-
Red Blood Cells: While anemia, or low red blood cell count, can occur in some COVID-19 individuals, there is no proof that blood transfusions will help these patients recover. Patients with illnesses such as sickle cell disease should keep getting their regular treatments, such as blood transfusions and iron-removing drugs.
-
White Blood Cells: It has been demonstrated that steroids such as Dexamethasone might lessen inflammation in COVID-19 patients, enhancing their prognosis. Using bone marrow stem cells to strengthen the immune system is one of the additional therapies under investigation. Although some studies have indicated potential for these treatments, obtaining approval for their usage can be costly and time-consuming.
Conclusion
Common blood-related problems with COVID-19 include elevated D-dimer and CRP values and low lymphocyte and platelet counts. These alterations are more pronounced in more severe cases and can be used to identify people who may benefit from intensive care or hospitalization. A pandemic makes it impractical to perform sophisticated blood testing; thus, physicians may use D-dimer levels over time to guide treatment decisions. It is critical to closely monitor blood coagulation problems and take action to minimize or prevent their effects.
